COVID-19-associated myocarditis: clinical pattern and medical treatment
DOI: 10.32364/2587-6821-2022-6-1-26-32
V.A. Sergeeva, T.E. Lipatova
V.I. Razumovskiy Saratov State Medical University, Saratov, Russian Federation
Myocarditis associated with the novel coronavirus infection (COVID-19) is a challenging diagnosis. Clinical presentations of this disease are either non-specific or occult. Meanwhile, long-term outcomes are unknown. Diagnostic approaches are challenging and virtually impossible to be applied in the COVID-19 hospitals. In addition, therapy for the COVID-19 infection is potentially harmful to the myocardium.
This review article summarizes currently available published data on the clinical aspects and medical treatment for inflammatory myocardial damage in the COVID-19 infection. More than 300 publications were analyzed. This paper addresses the most relevant information.
International published data provide strong evidence of the potential development of myocarditis secondary to the COVID-19 infection. Histological verification of myocardial damage is associated with significant differences since endomyocardial biopsy is not always possible in the setting of severe infection course. As a result, statistical data do not fully represent the prevalence of COVID-19-associated myocarditis. Pharmacotherapeutic strategies are generally empirical due to the understudied pathogenesis of inflammatory myocardial damage. Further studies are needed, given a controversial prognosis of COVID-19-associated myocarditis.
Keywords: COVID-19, SARS-CoV-2, myocarditis, myocardial damage, cardiovascular system, clinical presentations, treatment, drug effects.
For citation: Sergeeva V.A., Lipatova T.E. COVID-19-associated myocarditis: clinical pattern and medical treatment. Russian Medical Inquiry. 2022;6(1):26–32 (in Russ.). DOI: 10.32364/2587-6821-2022-6-1-26-32.
About the authors:
Victoria A. Sergeeva — C. Sc. (Med.), associate professor of the Department of Therapy with the Courses of Cardiology, Functional Diagnostics, and Geriatrics, V.I. Razumovskiy Saratov State Medical University; 112, Bolshaya Kazach’ya str., Saratov, 410012, Russian Federation; ORCID iD 0000-0003-3517-8231.
Tatjana. E. Lipatova — D. Sc. (Med.), Head of Department of Therapy with the Courses of Cardiology, Functional Diagnostics, and Geriatrics, V.I. Razumovskiy Saratov State Medical University; 112, Bolshaya Kazach’ya str., Saratov, 410012, Russian Federation; ORCID iD 0000-0002-7401-9930.
Contact information: Victoria A. Sergeeva, e-mail: viktoriasergeeva@mail.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 17.11.2021.
Revised 10.12.2021.
Accepted 11.01.2022.
2. Клинические рекомендации. Диагностика и лечение миокардитов. 2020 (Электронный ресурс.) URL: http://www.scardio.ru/content/Guidelines/2020/Clinic_rekom_Miokardit.pdf (дата доступа: 09.10.2021). [Clinical guidelines. Diagnosis and treatment of myocarditis. 2020 (Electronic resource.) URL: http://www.scardio.ru/content/Guidelines/2020/Clinic_rekom_Myokardit.pdf (access date: 09.10.2021) (in Russ.)].
3. Xiong T.Y., Redwood S., Prendergast B., Chen M. Coronaviruses and the cardiovascular system: acute and longterm implications. Eur Heart J. 2020;2:1–3. DOI: 10.1093/eurheartj/ehaa231.
4. Chen L., Li X., Chen M. et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116:1097–1100. DOI: 10.1093/cvr/cvaa078.
5. Kawakami R., Sakamoto A., Kawai K. et al. Pathological evidence for SARS-CoV-2 as a cause of myocarditis: JACC Review Topic of the Week. J Am Coll Cardiol. 2021;77(3):314–325. DOI: 10.1016/j.jacc.2020.11.031.
6. Wenzhong L., Hualan L. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism (Electronic resource.) URL: https://chemrxiv.org/engage/chemrxiv/article-details/60c74fa50f50db305139743d (access date: 15.10.2021). DOI: 10.26434/chemrxiv.11938173.v8.
7. Verdecchia P., Cavallini C., Spanevello A., Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020;76:14–20. DOI: 10.1016/j.ejim.2020.04.037.
8. Driggin E., Madhavan M.V., Bikdeli B. et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75(18):2352–2371. DOI: 10.1016/j.jacc.2020.03.031.
9. Long B., Brady W.J., Koyfman A. et al. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;18:1–4. DOI: 10.1016/j.ajem.2020.04.048.
10. Ho J.S., Sia C.H., Chan M.Y. et al. Coronavirus-induced myocarditis: A meta-summary of cases. Heart Lung. 2020;49(6):681–685. DOI: 10.1016/j.hrtlng.2020.08.013.
11. Kariyanna P.T., Sutarjono B., Grewal E. et al. A Systematic Review of COVID-19 and Myocarditis. Am J Med Case Rep. 2020;8(9):299–305. DOI: 10.12691/ajmcr-8-9-11.
12. Practice of echocardiography during the COVID-19 pandemic: guidance from the Canadian Society of Echocardiography (Electronic resource.) URL: http://csecho.ca/wp-content/uploads/2020/03/CSE-COVID-19-Guidance_English-1.pdf (access date: 15.10.2021).
13. Wichmann D., Sperhake J.P., Lütgehetmann M. et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med. 2020;173(4):268–277. DOI: 10.7326/M20-2003.
14. Ruan Q., Yang K., Wang W. et al. Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan. China Intens Care Med. 2020;6:1–4. DOI: 10.1007/s00134-020-06028-z.
15. Caforio A.L., Pankuweit S., Arbustini E. et al. European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636–2648. DOI: 10.1093/eurheartj/eht210.
16. Сергеева В.А., Шмойлова А.С. Клинические проявления инфекционного миокардита у мужчин и женщин. Клиницист. 2017;11:(4–1):45–49. [Sergeeva V.A., Shmoylova A.S. Clinical manifestations of infectious myocarditis in men and women. Klinicist. 2017;11(4–1):45–49 (in Russ.)].
17. Li L., Huang T., Wang Y. et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;92:577–583. DOI: 10.1002/jmv.25757.
18. Pirzada A., Mokhtar A.T., Moeller A.D. COVID-19 and Myocarditis: What Do We Know So Far? CJC Open. 2020;2(4):278–285. DOI: 10.1016/j.cjco.2020.05.005.
19. Cinar T., Hayiroglu M.I., Cicek V. et al. COVID-19 and acute myocarditis: current literature review and diagnostic challenges. Rev Assoc Méd Bras. 2020;66(2):48–54. DOI: 10.1590/1806-9282.66.S2.48.
20. Sawalha K., Abozenah M., Kadado A.J. et al. Systematic Review of COVID-19 Related Myocarditis: Insights on Management and Outcome. Cardiovasc Revasc Med. 2021;23:107–113. DOI: 10.1016/j.carrev.2020.08.028.
21. Castiello T., Georgiopoulos G., Finocchiaro G. et al. COVID-19 and myocarditis: a systematic review and overview of current challenges. Heart Fail Rev. 2021;27(1):251–261. DOI: 10.1007/s10741-021-10087-9.
22. Сергеева В.А., Елисеева С.П., Журавлева Е.В. Перипартальная кардиомиопатия: 10-летнее клиническое наблюдение. Фарматека. 2018;6(359):80–83. DOI: 10.18565/pharmateca.2018.6.80-83. [Sergeeva V.A., Eliseeva S.P., Zhuravleva E.V. Peripartum cardiomyopathy: 10-year clinical follow-up. Farmateka. 2018;6(359):80–83 (in Russ.)]. DOI: 10.18565/pharmateca.2018.6.80-83.
23. Kariyanna P.T., Sutarjono B., Grewal E. et al. A Systematic Review of COVID-19 and Myocarditis. Am J Med Case Rep. 2020;8(9):299–305. DOI: 10.12691/ajmcr-8-9-11.
24. Gunawardene M.A., Gessler N., Wohlmuth P. et al. Prognostic Impact of Acute Cardiovascular Events in COVID-19 Hospitalized Patients — Results from the CORONA Germany Study. J Clin Med. 2021;10(17):3982. DOI: 10.3390/jcm10173982.
25. Kochi A.N., Tagliari A.P., Forleo G.B. et al. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020;31(5):1003–1008. DOI: 10.1111/jce.14479.
26. Guo T., Fan Y., Chen M. et al. Association of cardiovascular disease and myocardial injury with outcomes of patients hospitalized with 2019-coronavirus disease (COVID-19). JAMA Cardiol. 2020;5(7):811–818. DOI: 10.1001/jamacardio.2020.1017.
27. Lindner D., Fitzek A., Bräuninger H. et al. Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. JAMA Cardiol. 2020;5(11):1281–1285. DOI: 10.1001/jamacardio.2020.3551.
28. Zhang H., Penninger J.M., Li Y. et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intens Care Med. 2020;46:586–590. DOI: 10.1007/s00134-020-05985-9.
29. Escher F., Pietsch H., Aleshcheva G. et al. Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies. ESC Heart Fail. 2020;7(5):2440–2447. DOI: 10.1002/ehf2.12805.
30. Goha A., Mezue K., Edwards P. et al. COVID-19 and the heart: An update for clinicians. Clin Cardiol. 2020;43(11):1216–1222. DOI: 10.1002/clc.23406.
31. Yang Z., Liu J., Zhou Y. et al. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020;81(1):13–20. DOI: 10.1016/j.jinf.2020.03.062.
32. Horby P., Lim W.S., Emberson J.R. et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693–704. DOI: 10.1056/NEJMoa2021436.
33. Doyen D., Moceri P., Ducreux D., Dellamonica J. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. Lancet. 2020;395(10235):1516. DOI: 10.1016/S0140-6736(20)30912-0.
34. Garot J., Amour J., Pezel T. et al. SARS-CoV-2 Fulminant Myocarditis. JACC Case Rep. 2020;2(9):1342–1346. DOI: 10.1016/j.jaccas.2020.05.060.
35. Liu B., Li M., Zhou Z. et al. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS). J Autoimmun. 2020;111:102452. DOI: 10.1016/j.jaut.2020.102452.
36. Echeverría-Esnal D., Martin-Ontiyuelo C., Navarrete-Rouco M.E. et al. Azithromycin in the treatment of COVID-19: a review. Expert Rev Anti Infect Ther. 2021;19(2):147–163. DOI: 10.1080/14787210.2020.1813024.
37. Trivedi N., Verma A., Kumar D. Possible treatment and strategies for COVID-19: review and assessment. Eur Rev Med Pharmacol Sci. 2020;24(23):12593–12608. DOI: 10.26355/eurrev_202012_24057.
38. Reiner Ž., Hatamipour M., Banach M. et al. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci. 2020;16(3):490–496. DOI: 10.5114/aoms.2020.94655.
39. Qiao W., Wang C., Chen B. et al. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology. 2015;131(2):97–106. DOI: 10.1159/000375362.
40. Amici C., di Caro A., Ciucci A. et al. Indomethacin has a potent antiviral activity against SARS coronavirus. Antivir Ther. 2006;11(8):1021–1030.
41. European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19 (Electronic resource.) URL: https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-antiinflammatories-covid-19 (access date: 01.09.2021).
42. Gao Y.D., Ding M., Dong X. et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76:428–455. DOI: 10.1111/all.14657.
43. Guo L., Shi Z., Zhang Y. et al. Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: A meta-analysis. Diabetes Res Clin Pract. 2020;166:108346. DOI: 10.1016/j.diabres.2020.108346.
44. Angeli F., Masnaghetti S., Visca D. et al. Severity of COVID-19: The importance of being hypertensive. Monaldi Arch Chest Dis. 2020;90:1372. DOI: 10.4081/monaldi.2020.1372.
45. Bonow R.O., Fonarrow G.C., O’Gara P.T., Yancy C.W. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol. 2020;5:751–753. DOI: 10.1001/jamacardio.2020.1105.
46. Giustino G., Croft L.B., Oates C.P. et al. Takotsubo Cardiomyopathy in COVID-19. J Am Coll Cardiol. 2020;76(5):628–629. DOI: 10.1016/j.jacc.2020.05.068.
47. D’Andrea A., Di Giannuario G., Marrazzo G. et al. The role of multimodality imaging in COVID-19 patients: from diagnosis to clinical monitoring and prognosis. G Ital Cardiol. 2020;21:345–353.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
